In August 2020, Clinart MENA was sold to CTI Clinical Trial & Consulting Services, marking a strategic expansion for CTI in the Middle East and North Africa region. Hybrid Capital served as the exclusive financial advisor to Clinart MENA in this transaction.
The acquisition enhanced CTI’s global clinical trial management capabilities and established a stronger presence in the MENA healthcare market. Clinart MENA’s expertise in clinical research and regulatory affairs complemented CTI’s existing service portfolio, creating enhanced value for pharmaceutical and biotechnology clients operating in the region.